Popular
News
Female Hair Loss Treatments - Surgical and Non Surgical
Hive Health Media (blog)
RepliCel Releases Positive Results from the Interim Analysis of Data from its
MarketWatch (press release)
The Company is delighted to report that the six-month interim analysis results support the continued development of DSCC for the treatment of androgenetic alopecia. "The assessment of the primary endpoint of the TS001-2009 clinical trial shows a
Hair today, gone tomorrow
Malaysia Star
Androgenetic alopecia afflicts 30% of men by the time they hit 30 years of age. It hits 90% of men when they reach 70. At that time, he thought hair loss could be “probably the worst thing to happen to a person”. He was so self-conscious of wearing a
Male baldness
Body and Soul
The most common reason for this is male-pattern-baldness (androgenic alopecia). It usually starts at the temples or on top of the head and leads to either partial or complete hair loss. The process can start as early as late teen years but it usually
Hair Replacement Business, Charle a Hair Studio, Opens New Location in Santa
Virtual-Strategy Magazine
People with conditions such as Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Androgenetic Alopecia (aka, hereditary thinning), Trichotillomania (hair pulling), Chemotherapy, Radiation, and so on, have traveled to Charle for the last 30 years
RepliCel Releases Positive Results from the Interim Analysis of Data from its
Healthcare Global (press release)
The Company is delighted to report that the six-month interim analysis results support the continued development of DSCC for the treatment of androgenetic alopecia. "The assessment of the primary endpoint of the TS001-2009 clinical trial shows a
Gone today…hair tomorrow?
Palm Beach Post
Whether the blood condition and hair degradation are causally connected, or merely coincidental, I'll never know (middle-age illness can trigger, or accelerate, androgenic alopecia). What I do know is that, when the universe sends you certain signals,
R-Tech Ueno: Completion of a Phase I Clinical Study of RK-023 for the
MarketWatch (press release)
About development code: RK-023 RK-023 is the new compound developed by R-Tech Ueno as a novel physiologically active fatty acid derivative for the treatment of androgenetic alopecia and hypotrichosis of the eyelashes. The completion of the Phase 2a
HairMax LaserComb Announces Reaching 10 Year Milestone and 5 Years of
Virtual-Strategy Magazine
The HairMax is the only laser phototherapy device to receive FDA 510(k) marketing Clearance; in 2007 for males and in 2011 for females for the treatment of androgenetic alopecia (pattern hair loss). In the over ten years of marketing the device
PCOS treatment in general practice
Irish Medical Times
Skin signs of hyperandrogenism — acne, hirsutism, seborrhoea, male pattern alopecia. • Fertility problems — it is the most common cause of anovulatory infertility. • Metabolic — PCOS is a major risk factor for development of type 2 diabetes.
